The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target

Future Oncol. 2016 Mar;12(5):595-600. doi: 10.2217/fon.15.337. Epub 2016 Feb 1.

Authors

Affiliations

¹ University of Birmingham Medical School, College of Medical & Dental Sciences, Birmingham, UK.
² Cancer Research Unit, University of Warwick, Coventry, UK.
³ University Hospital Birmingham NHS Foundation Trust, Birmingham, UK.
⁴ Heart of England NHS Foundation Trust, Birmingham, UK.
⁵ Institute of Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK.

PMID: 26880382
DOI: 10.2217/fon.15.337

No abstract available

Keywords: B7-H1; PD-1; PD-L1; bladder cancer; outcome; pathogenesis; target; urothelial carcinoma.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / drug effects
Antibodies, Monoclonal / pharmacology
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / genetics
B7-H1 Antigen / metabolism*
Disease Progression
Gene Expression Regulation, Neoplastic / drug effects
Humans
Molecular Targeted Therapy
Neoplasm Staging
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / genetics
Programmed Cell Death 1 Receptor / metabolism*
Signal Transduction* / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
Urinary Bladder Neoplasms / diagnosis
Urinary Bladder Neoplasms / drug therapy
Urinary Bladder Neoplasms / etiology*
Urinary Bladder Neoplasms / metabolism*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
Programmed Cell Death 1 Receptor